Page 2 - Mark Corbae News Today

/PRNewswire/ -- Phosplatin Therapeutics Inc., a clinical stage pharmaceutical company focused on oncology therapeutics, today announced the appointment of...

/PRNewswire/ -- Sirnaomics Ltd. ("Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics,...

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

/PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi...

Phase I clinical trial expected to initiate in second quarter 2022 HONG KONG, Feb. 16, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that they have received the "safe to proceed" letter from the U.S. Food and Drug Administration (FDA) for the Company's...

Press release content from PR Newswire. The AP news staff was not involved in its creation.

The Colorado Attorney General is investigating a Denver-based company that is the nation’s largest provider in a federal community-based home health program for frail, elderly patients, initiating the probe after

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in discovery and development of RNAi therapeutics against cancer and fibrotic diseases,...

Press release content from PR Newswire. The AP news staff was not involved in its creation.